Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ARTV
SELLArtiva Biotherapeutics, Inc. · Healthcare · United States · $487M · Avg Vol: $6M/d
COMPANY DESCRIPTION
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing off-the-shelf allogeneic natural killer (NK) cell therapies for various cancers. The company's proprietary platform aims to provide readily available and scalable cell therapy options, overcoming the manufacturing complexities and patient-specific limitations of autologous treatments. Its competitive edge is rooted in its innovative approach to leveraging NK cell biology to create potentially transformative cancer immunotherapies.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 4.9M | 33.5M | 0.3M | 0 | -77.4% | — | — | — | — |
| EPS | -7.67 | -3.12 | -0.67 | -2.90 | -3.43 | — | -3.34 | -2.43 | -2.81 | — |
| Shares | — | 48.6M | 48.6M | 48.6M | 24.6M | -49.4% | — | — | — | — |
| Debt | — | 19.4M | 16.9M | 14.4M | 10.9M | -17.4% | 10.3M | — | — | — |
| Equity | — | -140.7M | -162.0M | 186.6M | 110.0M | -41.1% | — | — | — | — |
| Op CF | — | -50.8M | -47.4M | -55.0M | -76.8M | — | -77.9M | — | — | — |
| Inv CF | — | -6.3M | -26.0M | -120.5M | 63.4M | — | — | — | — | — |
| Fin CF | — | -1.3M | 24.4M | 162.2M | 9.0K | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ARTV are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ARTV | Artiva Biotherapeutics, Inc.(you) | $487M | 26 | SELL |
| ASMB | Assembly Biosciences, Inc. | $506M | 24 | SELL |
| RZLT | Rezolute, Inc. | $480M | 23 | SELL |
| FDMT | 4D Molecular Therapeutics, Inc. | $526M | 27 | SELL |
| LRMR | Larimar Therapeutics, Inc. | $416M | 25 | SELL |
| PRTC.L | PureTech Health plc | $421M | 27 | SELL |
| ZURA | Zura Bio Limited | $496M | 21 | SELL |
| SGMT | Sagimet Biosciences Inc. | $437M | 28 | SELL |
| CBIO | Crescent Biopharma, Inc. | $602M | 25 | SELL |
| NVCT | Nuvectis Pharma, Inc. | $609M | 25 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%